Table 1.
Characteristic | Infliximab (n = 1,060) | Adalimumab (n = 391) | p-value |
---|---|---|---|
Age [Mean(SD)] (in years) | 34.1 (0.5) | 35.2 (0.7) | 0.21 |
Female (%) | 53 | 56 | 0.31 |
Charlson score [Mean(SD)] | 2.9 | 2.8 | 0.43 |
Disease duration*[Mean(SD)] (in years) | 2.9 (0.1) | 4.8 (0.2) | < 0.001 |
Type of IBD (%) | < 0.001 | ||
Crohn’s disease | 68 | 79 | |
Ulcerative colitis | 32 | 21 | |
Prior anti-TNF exposure (%) | 18 | 49 | < 0.001 |
Prior IBD hospitalization (%) | 45 | 50 | 0.08 |
Prior IBD surgery (%) | 7 | 17 | < 0.001 |
Highest C-reactive protein [Mean(SD)] (mg/dL)+ | 32.0 (2.6) | 22.6 (3.3) | 0.03 |
IBD – inflammatory bowel diseases
Disease duration was defined as the interval between the first ICD-9 code for Crohn’s disease or ulcerative colitis and date of first codified mention of infliximab or adalimumab
available within 60 days prior to initiation of biologics for 340 patients on infliximab and 144 on adalimumab (Values < 8mg/dL are considered normal)